Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms iRucaparib-AMP3-2 |
Target |
Action degraders, inhibitors |
Mechanism PARP1 degraders(Poly (ADP-Ribose) polymerase 1 degraders), PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC46H54FN7O9 |
InChIKeyAHTWWIQPWVXFKF-UHFFFAOYSA-N |
CAS Registry2472644-76-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 28 Oct 2019 |